RECRUITING

Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

Talk to us

Conditions

GlioblastomaAnaplastic AstrocytomaAstrocytomaAnaplastic OligodendrogliomaAdaptive RadiotherapyHigh-grade gliomaPerfusion-weighted imagingDiffusion weighted imaging

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.

Official Title

Adaptive Radiotherapy Based on Multi-Parametric Diffusion- and Perfusion-weighted Magnetic Resonance Imaging in Patients With Newly Diagnosed High-Grade Glioma

Quick Facts

Study Start:2024-01-30
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06108206

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma
  2. * History and physical examination within 28 days prior to enrollment
  3. * Karnofsky performance status 70 or greater
  4. * Age 18 years or greater
  5. * Negative pregnancy test for females of childbearing potential before 1st research MRI, performed in accordance to institutional guidelines.
  6. * Plan to receive 59.4-60 Gy in 30-33 fractions of radiotherapy. Glioblastoma patients over 65 year-old can receive hypofractionated radiotherapy including 40 Gy in 15 fractions.
  1. * Prior therapy for tumor except for biopsy or resection, including prior radiotherapy to the brain.
  2. * Clinical or radiological evidence of metastatic disease outside the brain
  3. * Prior malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years

Contacts and Locations

Study Contact

Tony J. Wang, MD
CONTACT
212-305-5050
tjw2117@cumc.columbia.edu
Radiation Oncology Research Department
CONTACT
212-305-5050

Principal Investigator

Tony J. Wang, MD
PRINCIPAL_INVESTIGATOR
Columbia University

Study Locations (Sites)

Columbia University Irving Medical Center/NYPH
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Tony J. Wang, MD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-30
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2024-01-30
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • Adaptive Radiotherapy
  • High-grade glioma
  • Perfusion-weighted imaging
  • Diffusion weighted imaging

Additional Relevant MeSH Terms

  • Glioblastoma
  • Anaplastic Astrocytoma
  • Astrocytoma
  • Anaplastic Oligodendroglioma